MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Show more

9713 Key West Avenue, Rockville, MD, 20850, United States

Medical Devices
Healthcare

Market Cap

147.8M

52 Wk Range

$0.64 - $2.37

Previous Close

$1.38

Open

$1.37

Volume

1,061,953

Day Range

$1.37 - $1.44

Enterprise Value

59.0M

Cash

106.9M

Avg Qtr Burn

-8.169M

Insider Ownership

1.59%

Institutional Own.

68.19%

Qtr Updated

03/31/26


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date